X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Emergent will supply BioThrax® (Anthrax Vaccine Adsorbed) for use by all branches of the U.S. military as Pre-Exposure Prophylaxis (PrEP) for anthrax disease.
Lead Product(s): Anthrax Vaccine Adsorbed
Therapeutic Area: Infections and Infectious Diseases Product Name: Biothrax
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: $235.8 million Upfront Cash: Undisclosed
Deal Type: Agreement January 11, 2024
Details:
Under the agreement, Emergent has the option for the acquisition of newly licensed anthrax vaccine Cyfendus (anthrax vaccine adsorbed, adjuvanted), a vaccine indicated for post-exposure prophylaxis of anthrax disease.
Lead Product(s): Anthrax Vaccine Adsorbed, Adjuvanted
Therapeutic Area: Infections and Infectious Diseases Product Name: Cyfendus
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: BARDA
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Agreement November 28, 2023
Details:
NARCAN (naloxone) Nasal Spray will be the first, life-saving emergency medicine for opioid overdose available on shelves, for Everyone to Help Save a Life from an Opioid Overdose Emergency.
Lead Product(s): Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Narcan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
The agreement aims for the advanced development, manufacturing scale-up, and procurement of Ebanga (ansuvimab-zykl), a monoclonal antibody with antiviral activity provided through a single infusion, a licensed treatment for Ebola virus disease (EVD).
Lead Product(s): Ansuvimab-zykl
Therapeutic Area: Infections and Infectious Diseases Product Name: Ebanga
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $704.0 million Upfront Cash: Undisclosed
Deal Type: Agreement July 31, 2023
Details:
CYFENDUS™ (Anthrax Vaccine Absorbed, Adjuvanted) is a vaccine indicated for post-exposure prophylaxis of anthrax disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when given with recommended antibacterial drugs.
Lead Product(s): Anthrax Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Cyfendus
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2023
Details:
With the closing of the transaction, Bavarian Nordic acquires two marketed vaccines – Vivotif® (typhoid vaccine) for the prevention of typhoid fever and Vaxchora® for the prevention of cholera as well as a Phase 3 vaccine candidate for the prevention of Chikungunya virus.
Lead Product(s): Typhoid Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Vivotif
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Bavarian Nordic
Deal Size: $384.0 million Upfront Cash: $274.0 million
Deal Type: Acquisition May 15, 2023
Details:
Narcan® (naloxone HCI) Nasal Spray, as an OTC emergency treatment for known or suspected opioid overdose. Naloxone hydrochloride is an opioid antagonist that antagonizes opioid effects by competing for the same receptor sites.
Lead Product(s): Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Narcan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Details:
Narcan® (naloxone HCI) Nasal Spray, as an OTC emergency treatment for known or suspected opioid overdose. Naloxone hydrochloride is an opioid antagonist that antagonizes opioid effects by competing for the same receptor sites.
Lead Product(s): Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Narcan
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2023
Details:
Under the agreement Bavarian Nordic will acquire Vivotif® for the prevention of typhoid fever and Vaxchora® against cholera as well as a Phase 3 vaccine candidate for the prevention of Chikungunya virus.
Lead Product(s): Typhoid Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Vivotif
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Bavarian Nordic
Deal Size: $380.0 million Upfront Cash: $270.0 million
Deal Type: Acquisition February 14, 2023
Details:
Narcan® (naloxone HCI) Nasal Spray, as an OTC emergency treatment for known or suspected opioid overdose. Naloxone hydrochloride is an opioid antagonist that antagonizes opioid effects by competing for the same receptor sites.
Lead Product(s): Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Narcan
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
